Rising cases in Kitsap signals potential for severe flu season ahead

Washington state emergency-room visits for influenza have risen to 3.3% as of Dec. 27, surpassing the masking threshold in health-care settings and prompting Virginia Mason Franciscan Health to require staff masks starting Jan. 7; statewide ER use remains roughly 2 percentage points below last year’s peak that topped just over 8% and led to 507 seasonal deaths. Public-health officials report 22 lab-confirmed deaths so far and warn that circulation of the Type A Subclade K strain — linked to earlier and heavier outbreaks overseas — could make this a more severe season, sustaining demand for vaccines, PPE and hospital staffing resources despite vaccines still offering the best protection.

Analysis

Market structure: Rapid rise to 3.3% ER visits (exceeding masking thresholds) signals demand shock for vaccines, diagnostics and acute-care services over the next 4–12 weeks. Clear winners: vaccine manufacturers (seasonal supply + ad hoc orders), large retail pharmacies (CVS/WBA) and diagnostics (LH/DGX) that scale vaccinations/testing; losers: discretionary travel/hospitality (AAL/UAL/MAR) and elective outpatient procedures that face cancellations and margin pressure. Hospital operators (HCA/UHS) see revenue mix shift to higher-cost emergency care, compressing margins even as toplines tick up.

Risk assessment: Tail risks include Subclade K causing hospitalization rate surge >8% ER visits (last year peak) which could force local mandates, staffing crises and elective-procedure freezes—this would materially hit Q1 revenue for airlines and elective-care REITs. Immediate (days) risk: local masking/mandates; short-term (weeks/months): rising claims/labor costs for health systems; long-term (quarters) risk: vaccine composition changes and liability/regulatory scrutiny. Hidden dependencies: vaccine uptake, supply contract timing, and winter respiratory co-infections (RSV/COVID).

Trade implications: Expect modest risk-off across equities with safe-haven demand into USTs (buy TLT) and gold (GLD); oil demand could dip 1–3% vs baseline if travel meaningfully weakens. Equities: favor long CVS (pharmacy), LH/DGX (testing) and select vaccine names (SNY/GSK/MRNA) via call spreads 6–12 week expiries; hedge with short positions in AAL/UAL or HLT. Options: buy protection (OTM puts) on hospital operators and airlines if ER visits cross 5% threshold.

Contrarian angles: Consensus may overprice vaccine winners if Subclade K substantially evades current vaccines—vaccine makers could see revenue delayed or offset by liability/returns; conversely, diagnostics may be underowned given recurring testing demand. Historical parallel: 2017–18 severe season boosted volumes but depressed margins due to staffing; therefore prefer operators with strong balance sheets and variable-cost levers rather than levered elective-care providers.

Key Decisions for Investors

• Establish a 2–3% long position in CVS Health (CVS) over next 1–2 weeks to capture vaccination revenues and retail testing; target +8–12% upside in 3 months if weekly ER visits rise above 5%, set hard stop-loss at -10%.
• Initiate 1.5–2% long in LabCorp (LH) or Quest Diagnostics (DGX) via 8–12 week call spreads (buy 12-week ATM calls, sell 25–30% OTM) anticipating increased testing; add another tranche if CDC national influenza positivity increases >3 percentage points in any two consecutive weeks.
• Establish 1–2% short position in American Airlines (AAL) or United (UAL) funded by profits from CVS/LH longs; if TSA throughput data falls >5% YoY for two consecutive weeks or ER visits >6%, increase short by 50%.
• Buy 0.5–1% of portfolio in TLT (or 10–15bps duration extension via 10y Treasury futures) and 0.5% in GLD as cross-asset hedges if equity volatility rises and flows to safe havens; trim if 10y yield reverts +25bps from current levels.
• Purchase 8–10 week OTM puts (5–7% OTM) on HCA (HCA) sized at 0.5% notional as insurance against margin compression from staffing/overtime costs if local ER visits hit >8% (last year peak), review after seasonal peak (by end of February).